Abstract The purpose of this manuscript is to critically evaluate the preoperative assessments of peritoneal metastases described to date. Recommendations regarding use of current modalities and an assessment of their reliability will be made.
Introduction
Progress in the management of peritoneal metastases from gastrointestinal and gynecologic malignancy has continued over the last three decades. Cytoreductive surgery (CRS) with peritonectomy procedures and visceral resections have become well defined and are currently completed with minimal morbidity and mortality [1, 2] . The second component of peritoneal metastases treatment is hyperthermic perioperative chemotherapy (HIPEC). This has progressed but to this point in time standards of care have not been formulated. Currently, there is not a consensus regarding an optimal HIPEC with or without early postoperative intraperitoneal chemotherapy (EPIC) but steady progress has occurred [3] . Also, a reliable group of prognostic indicators including histopathology, prior surgical score (PSS), peritoneal cancer index (PCI), and completeness of cytoreduction score (CC score) have been validated in peritoneal metastases from both gastrointestinal and ovarian cancer [4] . There is one extremely important aspect of peritoneal metastases management that has lagged far behind the others. That is accurate preoperative assessment of the extent and distribution of the peritoneal surface malignancy. This accurate assessment prior to the abdominal exploration would be of great benefit. It would reduce the number of open and close procedures in patients having CRS plus HIPEC. Accurate knowledge regarding extent and distribution of peritoneal metastases (preoperative PCI) would provide crucial information to the surgeon and to the patient regarding the resection required for complete CRS and the likelihood of long-term benefit. Finally, accurate assessments would allow a stratification of patients so that a comparison between institutions of results of treatment is possible.
The purpose of this manuscript is to critically evaluate the preoperative assessments of peritoneal metastases described to date. Recommendations regarding use of current modalities and an assessment of their reliability will be made.
Histopathology Including Lymph Node Status
The histopathology of a gastrointestinal cancer has almost always been determined prior to an intervention using CRS and HIPEC to treat peritoneal metastases. Histopathology may be of great value in the preoperative evaluation of patients. For appendiceal epithelial neoplasms, the peritoneal metastases may be determined to be disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinoma (PMCA), or peritoneal mucinous carcinoma with signet ring morphology (PMCA-S). Figure 1 shows the marked difference in survival of DPAM and PMCA [5] . In this assessment PMCA includes the PMCS-S histologies. In this same group of PMCA patients, Ihemelandu and Sugarbaker identified patients who had signet ring or adenocarcinoid morphology. In the 80 appendiceal peritoneal metastases patients with signet ring morphology, median survival was 18.9 months as compared to 45.4 months for 361 PMCA patients in the absence of any signet ring cells. Median survival for 53 patients with adenocarcinoid morphology was 26.8 months (p = 0.000) [6] .
For colon cancer, signet ring peritoneal metastases also indicates a poor outcome with peritoneal metastases treated with CRS and HIPEC. Verwaal and colleagues reported 15 patients with signet ring cells had a median survival of 13.0 months as compared to 86 patients without signet ring cells identified in peritoneal metastases had a survival of 21.4 months (p = 0.008). These authors recommended that signet ring cells in peritoneal metastases are a relative contraindication to the use of CRS and HIPEC to treat peritoneal metastases in colon cancer patients [7] . Also, it is well established that signet ring cells carry a poor prognosis in patients with gastric cancer. In treating gastric cancer peritoneal metastases, signet ring cells indicate a near low likelihood for long-term survival for patients having CRS and HIPEC [8] .
Regional lymph node status of the primary appendiceal cancer has prognostic implications. In 273 PMCA patients, 47 were determined to have lymph nodes positive in the mesoappendix or in the ileocolic lymph node group. The patients treated with CRS and HIPEC with positive lymph nodes had a worse prognosis (Fig. 2) . However, the data on lymph node positive appendiceal metastases patients shows that the prognosis is sufficiently favorable to recommend CRS and HIPEC if complete cytoreduction is considered probable [5] .
Elias et al. in a multivariate analysis of 523 patients with colorectal cancer peritoneal metastases showed that positive regional lymph nodes indicated a reduced prognosis (p = 0.02) [9] . In colon cancer patients treated in Washington, DC with CRS and HIPEC for peritoneal metastases, 14 had no regional lymph node metastases and 53 had positive lymph nodes identified. Figure 3 shows the difference in survival by lymph node status (p = 0.03). Clearly, negative lymph nodes indicate an improved prognosis when peritoneal metastases are treated by CRS and HIPEC [10] .
Prior Surgical Score (PSS)
In a large majority of patients, if peritoneal metastases are treated with CRS and HIPEC, there are surgical procedures performed prior to the definitive procedure. The extent of prior surgery can be quantitated using an assessment called the prior surgical score (PSS) shown in Fig. 4 . The PSS will estimate the adhesive process that the surgeon will encounter during the reoperative event. More importantly it is an estimate of the extent of tumor cell entrapment that has occurred and will need to be resected as part of a complete CRS [12] . If only a biopsy was performed, the PSS is zero. If there was a prior exploratory laparotomy and a single abdominopelvic region was dissected, the PSS is one. If two to five regions are previously dissected, the PSS is two. If there was a prior attempt at cytoreduction and more than five abdominopelvic regions were involved in the surgical procedure, the PSS is three [11] .
For appendiceal mucinous neoplasms with DPAM histology, PSS had a profound effect on survival in patients treated with CRS and HIPEC. Ten-year survival with PSS 0-2 was 75 % as compared to 55 % with PSS of 3 (p < 0.0001). For PMCA, the PSS had less effect with a p = 0.0228 [5] .
A high prior surgical score has not been shown to affect prognosis with colon cancer. However, extensive prior dissection with rectal cancer in the pelvis has a profound effect on prognosis in treating peritoneal metastases. Sugarbaker reported a median survival of 35 months and a five-year survival of 40 % for colon cancer patients having a complete CRS. In contrast, rectal cancer patients having the same treatments had a median survival of 17 months and there were no longterm survivors [10] . Verwaal showed that the prognosis of rectal cancer patients treated for peritoneal metastases was markedly reduced (p = 0.069) [7] . A similar phenomenon was reported by Yang et al. in the prospective randomized trial of gastric cancer patients treated with CRS and HIPEC for peritoneal metastases. Patients treated for primary gastric cancer with peritoneal metastases had twice the survival when CRS and HIPEC were used as compared to CRS alone. However, those patients who had CRS and HIPEC for recurrent gastric cancer with peritoneal metastases failed to show benefit [13] . If neoadjuvant intraperitoneal and systemic chemotherapy was used, the differences in synchronous versus metachronous patients with peritoneal metastases was absent [14] . Cancer cells entrapped in the pelvis as a result of rectal cancer surgery or within the left upper quadrant of the abdomen with gastric cancer cannot have a complete CRS because of tumor cell entrapment at anatomic sites impossible to dissect free of peritoneal metastases.
An extreme example of prognosis determined by PSS was reported by Look and Sugarbaker for ovarian cancer [14] . They studied the clinical features of 28 ovarian cancer patients who had CRS and HIPEC for recurrent ovarian cancer. As would be expected, complete versus incomplete cytoreduction was a significant feature (p = 0.037). However, PSS was an equally robust clinical feature determining prognosis (p < 0.001) (Fig. 5) . Preoperative CT All patients being evaluated for CRS and HIPEC have a preoperative CT or MRI. In patients with non-mucinous cancer PET-CT is frequently obtained. The first priority in evaluating this study is the assessment of metastatic disease at systemic sites and in the liver. A second goal of preoperative CT is an assessment of the anatomic sites and lesion size of peritoneal metastases. Also, an estimate of visceral involvement is desired. This second assessment is referred to as the CT-PCI.
Jacquet and colleagues evaluated the abdominal and pelvic CT performed with both systemic and maximal oral contrast. The CT findings were recorded for all nine abdominopelvic regions. The size and number of each cancer nodule or mass was recorded. These observations were prospectively recorded for the CT and were compared to those observed at the time of abdominal exploration and during the cytoreductive surgical procedure. Figure 6 shows the results of this study [15] .
Small peritoneal nodules or masses less than 0.5 cm were detected at only 28 %. Moderate size nodules 0.5 to 5.0 cm were detected at 72 % and gross nodules greater than 5 cm at 90 %. These authors concluded that the accuracy of CT in peritoneal metastases was greatly dependent on lesion size. When the nine abdominopelvic regions were compared, the pelvic region was the least accurate.
Koh and colleagues performed a similar lesion by lesion analysis comparing preoperative CT with interpretative findings [16] . For lesion size less than 0.5 cm the sensitivity was only 11 %. For nodules 0.5 to 5.0 cm the sensitivity was 37 % and for nodules greater than 5 cm the sensitivity was 94 %. Koh et al. concluded that the sensitivity of CT was influenced by lesion size and that CT-PCI significantly underestimated the clinical PCI.
Yun and coworker published important observations concerning the CT-PCI in 76 patients [17] . The detection rate was highest for appendix peritoneal metastases (84 %) and lowest for gastric (47 %). The sensitivity of preoperative CT was influenced by histologic type (mucinous versus nonmucinous) tumor size and tumor location.
An example of the inaccuracy of the preoperative CT was demonstrated in a 60 year old woman had gastric cancer with signet ring morphology and a complete radiologic response to neoadjuvant chemotherapy. She developed gastric outlet obstruction approximately two months after completion of chemotherapy and was evaluated for palliative surgery. Laparoscopy showed a few minute peritoneal metastases. CT-PCI was zero. At surgery the clinical PCI was 18 and the cytoreductive surgery with total gastrectomy resulted in a postoperative PCI of 7 (Fig. 7) . Figure 8 shows the peritoneal metastases diffusely penetrating into the subperitoneal lymphatic system of the small bowel mesentery.
The concept of concerning radiologic features identified on preoperative CT has been used to help select patients for complete cytoreduction. The list of 13 concerning radiologic features is shown in Table 1 . Rivard and colleagues in their study of radiologic features reported that no single adverse image was associated with unresectability. However, it did have an impact on the outcome [18] . Statistically significantly patients with two or more concerning features were more likely to have a suboptimal cytoreduction (87.5 % for 2 features and 36.4 % for a single feature, p = 0.035).
The importance of concerning radiologic features was explored by Jacquet and colleagues for patients with mucinous peritoneal metastases being considered for cytoreductive surgery. Twenty-five patients with complete CRS were compared to 20 with incomplete CRS. The groups were assessed by presence versus absence of 16 CT radiologic features [19] . If a patient by preoperative CT had bowel segments obstructed by tumor, the complete CRS occurred in 12 %. If in addition tumor volume was equal to or greater than 0.5 cm on jejunum or upper ileum, no patients had complete CRS. Again in this study two concerning radiologic features were associated with incomplete cytoreduction.
Yan and colleagues retrospectively studied 30 patients with peritoneal mesothelioma who had an adequate versus suboptimal CRS [20] . Thirty-nine CT parameters were scored in the two groups of patients. A decision tree analysis was performed. If the CT showed a tumor mass greater than 5 cm in the epigastric region a suboptimal cytoreduction occurred in 78 % of patients. In an absence of a tumor mass greater than 5 cm only 19 % had a suboptimal CRS. If patients had class III involvement of small bowel regions in addition to tumor size greater than 5 cm in small bowel regions the suboptimal CRS occurred in 100 % of patients. If both of these radiologic parameters were absent, the suboptimal CRS was only 6 %.
In summary, in these three radiologic studies of the impact of concerning radiologic features on complete versus incomplete cytoreduction, a single concerning radiologic feature indicated a reduced but not absent complete CRS. However, the identification of two concerning radiologic features indicated that an adequate CRS was very unlikely.
Response to Neoadjuvant Chemotherapy
In many clinical situations in the management of peritoneal metastases, neoadjuvant chemotherapy (NAC) is indicated prior to a final decision to perform CRS and HIPEC. The evidence that response to NAC predicts a favorable prognosis with CRS and HIPEC is well established. Bijelic identified 10 of 34 patients with appendiceal mucinous carcinoma with peritoneal metastases treated with NAC using FOLFOX who had a complete or near-complete response by a study of the tissue specimens resected [21] . Figure 9 shows the remarkable prolonged survival of patients who had a marked NAC response as compared to those with a partial or absent response.
Passot performed a similar study in colon or rectal cancer patients with peritoneal metastases who had a NAC prior to CRS and HIPEC. Twelve patients had a complete response, 23 had a major response and 80 had a minor or no response [22] . The three groups of patients had a marked difference in survival (p = 0.0019). These survival Fig. 7 60 year old woman with signet ring gastric adenocarcinoma of the stomach and increasing gastric outlet obstruction despite after complete clinical response to neoadjuvant chemotherapy Fig. 8 60 year old woman with signet ring adenocarcinoma of the stomach. At surgery peritoneal metastases were in subperitoneal lymphatics differences were determined by an assessment of histopathologic specimens removed at the time of CRS and HIPEC. They concluded that histopathologic response to NAC was a new prognostic tool for the management of peritoneal metastases from colorectal cancer.
In a study of gastric cancer with peritoneal metastases, Fujiwara performed serial laparoscopy to assess the effects of neoadjuvant intraperitoneal and systemic chemotherapy [23] . These patients in whom peritoneal metastases disappeared and peritoneal nodules were no longer visible went on to have gastrectomy with CRS and HIPEC. This group of patients had a statistically significant improved outcome (p = 0.0173). A reliable evaluation of response to neoadjuvant chemotherapy in the absence of serial laparoscopy has not been published.
Changes in the level of tumor markers before and after NAC may be of help in the evaluation of response. This has been used as a reliable assessment of the extent of ovarian cancer using CA125 tumor marker. Carcinoembryonic antigen (CEA) and CA19-9 may change suggesting a response but the reliability of this decrease has not been determined. Also, there may be changes in radiologic imaging before and after NAC. However, in the absence of laparoscopy, a reliable indicator of response to NAC with published data regarding major response (true positive ratio) or lack of response (true negative ratio) have not been published.
Accurate data regarding the response to NAC would help in the preoperative assessment of patients who are considered for CRS and HIPEC. In Table 2 , the benefits of CRS and HIPEC after NAC are summarized for patients with colorectal cancer. In those 10 % of patients who have a complete response, CRS and HIPEC are of questionable benefit for prolonging survival. Generous use of biopsies is helpful in staging but extensive peritonectomy or visceral resections are not indicated; HIPEC is not likely to be of value either. If complete response could be established by an accurate preoperative assessment, the exploratory laparotomy could be avoided.
In those 70 % of patients who have a minor response or no response, CRS and HIPEC may be of benefit but perhaps of reduced benefit. These patients should not be denied the possible benefits of CRS and HIPEC [16] . However, if multiple cycles of systemic FOLFOX chemotherapy have not caused a response, HIPEC with intraperitoneal oxaliplatin and systemic 5-fluorouracil is not indicated. A HIPEC regimen of mitomycin C or mitomycin C plus doxorubicin is a better plan. Again, an assessment of NAC response preoperatively would be of benefit. In those 20 % of patients with a major response that falls short of complete response, a reduced number of cancer cells will remain behind in scar tissue that was once cancer tissue. This may be a challenging CRS. The HIPEC should probably be the same as was used for NAC for a continued chemotherapy effect. Accurate information regarding a major response prior to CRS and HIPEC would be of benefit in planning the intervention.
Normograms
Three attempts to establish normograms to assess prognosis have been published to date. None has gained wide acceptance. However, the concept of a simple assessment that could preoperatively estimate the outcome after CRS and HIPEC would be of great utility. Verwaal et al. published the prognostic score (PS); this assessment used five prognostic features that were each assigned a constant number. The lower the score, the better the response [24] .
Cashin and coworkers constructed their normogram from 9 different clinical variables. This COREP score varied from 0 to 18 with a low score indicating a poor prognosis [25] . Pelz and colleagues published data on the Peritoneal Surface Disease Severity Score or PSDSS [26] . The numerically weighted clinical symptoms, CT-PCI and primary cancer histology to calculate a score from 2 to 22 that would estimate the outcome expected from a CRS and HIPEC procedure ( Table 3 ). The PSDSS has been used to estimate outcome for ovarian cancer as well as colon cancer.
Summary
A preoperative assessment of prognosis is required for improved management of patients with peritoneal metastases. The histopathology of the primary cancer and its peritoneal metastases is a requirement of the patient selection process. The PSS will give an estimate of the extent of tumor cell entrapment. Although the clinical PCI determined at the time of abdominal exploration is of great value in predicting the outcome of CRS and HIPEC, unfortunately an assessment of the extent of disease by CT-PCI is not of sufficient accuracy to be useful.
The CT is of more use to identify the concerning radiologic features. One concerning radiologic feature indicates a reduced prognosis while two concerning radiologic features suggests that CRS and HIPEC will not achieve a complete CRS. Although difficult to assess preoperatively, response to NAC has a profound impact on prognosis and the way in which CRS and HIPEC should be administered. Normograms to estimate the success of CRS and HIPEC have been published; the normogram PSDSS is sufficiently simple and applicable in different diseases to merit further application. 
